Compare TLF & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLF | JSPR |
|---|---|---|
| Founded | 1980 | 2018 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.2M | 14.9M |
| IPO Year | 2006 | N/A |
| Metric | TLF | JSPR |
|---|---|---|
| Price | $2.33 | $0.49 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 39.4K | ★ 657.7K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 32.05% | N/A |
| EPS Growth | ★ 1122.22 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $76,324,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $78.33 | ★ N/A |
| Revenue Growth | ★ 2.60 | N/A |
| 52 Week Low | $2.20 | $0.42 |
| 52 Week High | $3.78 | $7.19 |
| Indicator | TLF | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 47.91 | 33.53 |
| Support Level | $2.25 | $0.42 |
| Resistance Level | $2.45 | $1.02 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 32.35 | 30.39 |
Tandy Leather Factory Inc is a specialty retailers of leather and leathercraft-related items. Its primary line of business is the sale of leather, leather crafts, and related supplies. Its broad line of leather and related products includes leather, leatherworking tools, leather dyes and finishes, and do-it-yourself kits. Its products include Leather, tools, Hardware, Supplies, Kits, Books and Patterns, and Gift cards. The company sells its products primarily through company-owned stores and through orders generated from its global websites, and through direct account representatives in its commercial division. Geographically the company operates within the United States, and Canada. it generates the highest revenue from the United States.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.